Shield Therapeutics Share Discussion Threads

[halland75] 21/2/2024 17:12

Bad luck to all those who sailed in this.

The same characters I should imagine who have been in ENET and AGL.

Triple bad luck!

[bones698] 21/2/2024 16:53

Fast running out of money and bills mounting up. It's either a heavily discounted placing or fire sale now. They messed up big time overspending and not slashing costs and gojng after revenue but no profits and now they came in low end they are going to get hammered. If you can't make a profit on that revenue time to give up.

Cash flow positive in h2 2025. Like they will get anywhere near there given the current situation. Total disaster and only reacting far to late to save cash. This is one to avoid given management seem totally inept and clueless

[luckygit] 21/2/2024 16:37

At this point in Shields present predicament and it's questionable business plan, a suitor with a similar business, with it's own sales force may very well come in with a takeover. Especially at the present share price. With over 100 sales personnel in the USA burning cash every day, that's where the axe would fall with a new owner.

[weatherman] 21/2/2024 16:34

Maybe some take us out for 6p - better than another deep discounted rights issue.

[tripletop1] 21/2/2024 15:50

135m traded.. with the stock down 50%

defintely some rotation today from some massive sellers to (brave) background buyer(s)

only salvation to steady the ship is if GM and fellow directors made significant purchases

and/or

AOP strenghtening their controlling interest

[bos1234] 21/2/2024 15:35

Based on all the data I can find my analysis of their position suggests at a 30% quarterly growth rate in US prescriptions and a monthly cash burn of $4m they would not need additional funds.
Conversely
At a 20% quarterly increase in US prescriptions and a $3.3m monthly cash burn of $3.3m they would also not need additional funds.
However
I believe at a monthly cash burn of $4m and a quarterly growth rate of 20% they will go cash negative in Q3 2024 and run up at total debt of $6.8m by Q12025. They then break even at end of Q2 2025 and generate cash to completely pay of the debt by end of 2025.
This is the scale of the challenge for the CFO.

[alancapone] 21/2/2024 14:59

Salvage what you can

[blackhorse23] 21/2/2024 14:29

Money moving to APH [LSE] , excellent growing health care company

[oldtimer169] 21/2/2024 13:52

Tomorrow promises to be a baptism of fire for the new CFO

[dealit] 21/2/2024 13:38

STX have A proven product in Accrufer® which does sell well. Maybe a buyer is on the horizon.

[pwhite73] 21/2/2024 13:32

There is no reason to disbelief him. The stock has started tanking afresh because there is a significant holder(s) selling who have not finished yet or the markets have now got wind of a discount placing.

How do you think people are buying 1000000 at 2.60p?

[dealit] 21/2/2024 13:19

Do investors on this B/B disagree with the CEOs statement totally:- Greg Madison, CEO of Shield Therapeutics, said: "The progress made in the market in 2023 has shown us that the opportunity for Accrufer® continues to be significant. Quarterly prescription numbers grew throughout the year and we saw a significant improvement in the average net selling price in the second half. I'm also excited our new CFO, Santosh Shanbhag, has joined the team bringing both strategic and financial leadership to our organization. Our partnership with Viatris continues to progress very well and we remain steadfast in our goal to make Accrufer® the oral iron of choice for patients."

[ny boy] 21/2/2024 13:12

The markets don’t agree with you on this, don’t ignore the markets

[qipincha] 21/2/2024 11:43

also, 2024-2025 is critical time for the deal with China:

Shield Therapeutics ties up US$63mln deal for Feraccru in China in 2020


there was an upfront payment of US$11.4mln(£9.7 million from ASK Pharma in China in 2020)

reported in Feb 2022: completed a pharmacokinetics study in China, a
critical regulatory requirement and are now enrolling patients in the Phase 3 trial
hxxps://ir.design-portfolio.co.uk/viewer/97/30432

Shield is eligible to receive a further US$11.4 million upon regulatory approval of Feraccru®/Accrufer® in China.
hxxps://ir.design-portfolio.co.uk/viewer/97/36074

estimate a launch in 2025 and ascribe a 75% probability of approval.
hxxps://www.edisongroup.com/research/shield-therapeutics-ramped-up-and-heading-into-a-stronger-h223/32719/

-----------------
as the last update regarding this was in Feb 2022, given the timeframe of phase 3 trial and application, news regarding approval likely come in this year.

[dexdringle] 21/2/2024 11:21

Yes, it's always a good idea to wait for a share to increase 12 fold before buying 🙄

[ny boy] 21/2/2024 11:02

Just for gamblers, not a serious investment just another confetti share, more dilution on the next raise. The markets are rarely wrong imo

If this ever gets above 40p again, I will definitely consider a stake but the way things are panning out 5p looks tops.

[amaretto1] 21/2/2024 10:58

Going to be far far better than this !!!

[qipincha] 21/2/2024 10:58

the figures are more realistic to me, hope this is due to the new CFO?

[weatherman] 21/2/2024 10:37

A good growth story really for a pharma co with impressive growth in sales - just a shame the finances are a mess.

[paul planet earth 1] 21/2/2024 10:34

Ameretto - how’s your APTA? 🤣🤣🤣